Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KMT2A | Q03164 | 3/20 | 0.65 |
| ▸ | MEN1 | O00255 | 1/20 | 0.65 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.59 |
| ▸ | RAB9A | P51151 | 1/20 | 0.58 |
| ▸ | EPHX2 | P34913 | 3/20 | 0.53 |
| ▸ | HSD11B1 | P28845 | 1/20 | 0.49 |
| ▸ | POLB | P06746 | 1/20 | 0.48 |
| ▸ | P2RX7 | Q99572 | 2/20 | 0.47 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.46 |
| ▸ | HPGD | P15428 | 1/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2405650 | 0.81 | MEN1 (0.52) | KMT2AMEN1SMN1; SMN2RAB9AEPHX2 | |
| SCHEMBL2405652 | 0.81 | MEN1 (0.52) | KMT2AMEN1SMN1; SMN2RAB9AEPHX2 | |
| SCHEMBL2404960 | 0.81 | HDAC6 (0.55) | KMT2AMEN1SMN1; SMN2EPHX2ALDH1A1 | |
| SCHEMBL2404962 | 0.81 | HDAC6 (0.55) | KMT2AMEN1SMN1; SMN2EPHX2ALDH1A1 | |
| SCHEMBL3322052 | 0.80 | KMT2A (0.74) | KMT2AMEN1SMN1; SMN2RAB9AEPHX2 | |
| SCHEMBL2403181 | 0.79 | EPHX2 (0.41) | KMT2AMEN1SMN1; SMN2RAB9AEPHX2 | |
| Adamantane SCHEMBL3322185 | 0.79 | KMT2A (0.72) | KMT2AMEN1SMN1; SMN2RAB9AEPHX2 | |
| SCHEMBL2407868 | 0.78 | HDAC3 (0.71) | KMT2AMEN1SMN1; SMN2RAB9AEPHX2 | |
| SCHEMBL2403209 | 0.78 | HDAC3 (0.71) | KMT2AMEN1SMN1; SMN2RAB9AEPHX2 | |
| SCHEMBL3320032 | 0.77 | KMT2A (0.74) | KMT2AMEN1SMN1; SMN2RAB9AEPHX2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20110212943-A1 | NOVEL BRIDGED CYCLIC COMPOUNDS AS HISTONE DEACETYLASE INHIBITORS | ORCHID RESEARCH LABORATORIES LIMITED (IN) | 2011-09-01 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110212943-A1 | NOVEL BRIDGED CYCLIC COMPOUNDS AS HISTONE DEACETYLASE INHIBITORS | HDAC1, HDAC11, HDAC7 | KMT2A 328/4885MEN1 2434/4885SMN1; SMN2 3730/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.